GLP-1 Market
LLY $1251.61 ▲ +3.5% NVO $39.22 ▲ +2.9% PFE $29.44 ▲ +0.8% VKTX $27.37 ▲ +7.5% KLRA $11.71 ▲ +9.0% GPCR $22.19 ▲ +1.4% RHHBY $56.78 ▲ +2.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Luseogliflozin

Company
Aimi Fadilah Mohamad
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 16, 2026

Find a Clinical Trial Near Me

See recruiting studies for Luseogliflozin and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07433192

    POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes.

    Servier Russia 300 participants Est. completion 2027-09-01 1 site
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02284269

    Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus

    Pharmaceuticals and Medical Devices Agency, Japan 18000 participants
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02500186

    The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor

    Not yet reported Kansai Electric Power Hospital 24 participants Est. completion 2015-12 Stand-alone
    Other conditions: Diabetes Melltius, Type 2
    View official trial listing →
  • Status unknown NCT NCT02528019

    Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

    Not yet reported Kurume University 100 participants Est. completion 2018-08 1 site
    Other conditions: Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
    View official trial listing →
  • Completed NCT NCT07876258

    A Study in Type 2 Diabetes Patients Who Are Taking Moderate Dose Insulin, Looking at the Effects of the Medication Luseogliflozin on Risk of Ketoacidosis and Insulin Resistance.

    Not yet reported Aimi Fadilah Mohamad 40 participants Est. completion 2024-11-30 1 site
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.